Martin Godbout holds a B.Sc. in biochemistry (1979) and a Ph.D. in physiology and molecular endocrinology from Laval University. From 1985 to 1990, he received a postdoctoral fellowship from the Medical Research Council (MRC) of Canada and went to San Diego, California, where he was trained in Neuromolecular Biology, at The Scripps Research Institute.

In 1991, Dr. Godbout came back to Laval University as an Asssistant Professor at the Department of Psychiatry at the Faculty of Medicine. The same year, the Quebec Foundation for Mental Disorder awarded Dr. Godbout the Grand Prix Recherche for his previous works on Alzheimer's disease. From December 1993 to April 1994, he was Assistant Managing Director responsible for biopharmaceutical industry relations at the Research Centre of Centre Hospitalier de l’Université Laval (CHUL). In 1994, l'Université Laval awarded Dr. Godbout of the «Prix Summa» from the Faculty of Science and Engineering, and the same year, he founded BioContact Québec, an international biopharmaceutical partnership symposium. Since August 2005, Dr. Godbout has been named Officer of the Order of Canada.

From May 1994 to May 1997, he was named President and General Manager of Société Innovatech Québec, a $60 million technology investment fund. From May 1st 1997, Dr. Godbout was the Senior Vice-President of BioCapital, a Canadian venture capital firm specializing in seed-to-mezzanine stage private financing of companies demonstrating strong potential in the healthcare and biotechnology sectors. Since April 1st 2000, Dr Godbout is the President & CEO of Genome Canada, a private, not-for-profit Corporation, dedicated to investing and implementing a national strategy in genomics and proteomics research in Canada.

In March 2006, Dr. Godbout was shortlisted by the editors of Nature Biotechnology, as one of twenty nominees who have made the most remarkable and influential contribution to biotech in the past ten years in the category “Biobusiness in the rest of the world”. Dr. Godbout is presently a member of the board of directors of several Canadian biopharmaceutical companies, foundations and scientific Canadian organizations such as MethylGene, Confab Laboratories, AngioChem, Genome Canada, and BioContact Québec. Dr. Godbout has been a member of the Board of the "Conseil de la Science et de la Technologie du Québec" from 1996 to 2004. Dr. Godbout has authored or co-authored more than 60 publications and abstracts, and has been invited as speaker at numerous scientific and financial conferences.

President and CEO

Genome Canada
Ottawa, Ontario, Canada K2P 1P1

Phone: +1 (613) 751-4460 #114
Fax: +1 (613) 751-4474
mgodbout@hodran.com
www.genomecanada.ca